|
Title
|
|
|
|
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| 30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer. (C) 2003 Elsevier Science Ltd. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
European journal of cancer. - Oxford, 1990, currens
|
|
|
Publication
|
|
|
|
Oxford
:
2003
|
|
|
ISSN
|
|
|
|
0959-8049
[print]
1879-0852
[online]
|
|
|
DOI
|
|
|
|
10.1016/S0959-8049(03)00198-9
|
|
|
Volume/pages
|
|
|
|
39
:8
(2003)
, p. 1141-1143
|
|
|
ISI
|
|
|
|
000183056700026
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|